Nawara Sakpuwadol
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Nawara Sakpuwadol has a total of 15 co-authors. Here are the top co-authors by number of shared publications:
- Poonkiat Suchonwanit
Division of Dermatology, Department of Medicine, Faculty of Medicine, Ramathibodi Hospital, Mahidol University, Thailand
5 shared publications - Cherrin Pomsoong
Division of Dermatology, Department of Medicine, Ramathibodi Hospital, Mahidol University
3 shared publications - Kasama Tejapira
Division of Dermatology, Department of Medicine, Faculty of Medicine, Ramathibodi Hospital, Mahidol University, Bangkok, Thailand
3 shared publications - Suthinee Rutnin
Division of Dermatology, Department of Medicine, Faculty of Medicine, Ramathibodi Hospital, Mahidol University, Bangkok, Thailand
3 shared publications - Kunlawat Thadanipon
Department of Clinical Epidemiology and Biostatistics, Faculty of Medicine Ramathibodi Hospital, Mahidol University, Bangkok, Thailand
2 shared publications - Tanat Yongpisarn
Division of Dermatology, Faculty of Medicine Ramathibodi Hospital Mahidol University Bangkok Thailand
2 shared publications
Latest Publications
- Open Access
- 1 September 2026
- Published by Taylor & Francis in Clinical, Cosmetic and Investigational Dermatology
- Vol. ume 19, 1-8
Dupilumab for Drug-Induced Bullous Pemphigoid: A Case Series and Literature Review
Drug-induced bullous pemphigoid (BP) is an increasingly recognized variant of BP with unique challenges in management, particularly when patients require continuation of the offending medication or are contraindicated to conventional immunosuppressive therapies. We report 4 patients with drug-induced BP, three associated with dipeptidyl peptidase-4 inhibitors and one with immune checkpoint inhibitor, successfully treated with dupilumab. All four patients had failed or were intolerant to conventional therapies. Following dupilumab initiation, all patients experienced significant improvement in pruritus within 2 weeks. Complete remission was achieved in 3 patients within 1– 5 months of treatment and one patient had stable disease, enabling him to resume pembrolizumab therapy for esophageal cancer while on dupilumab. No significant adverse effects were reported during treatment periods. Our findings, supported by a literature review, suggest that dupilumab demonstrates promising efficacy and safety in treating drug-induced BP, with rapid improvement in pruritus and resolution of skin lesions. It may offer a valuable therapeutic alternative as a steroid sparing agent for elderly patients with multiple comorbidities and provides the potential to continue necessary medications (eg, cancer therapy) that may have triggered BP.
- 1 September 2026
- Published by Taylor & Francis in Clinical, Cosmetic and Investigational Dermatology
- Vol. ume 19, 1-8
Open AccessDupilumab for Drug-Induced Bullous Pemphigoid: A Case Series and Literature Review
Drug-induced bullous pemphigoid (BP) is an increasingly recognized variant of BP with unique challenges in management, particularly when patients require continuation of the offending medication or are contraindicated to conventional immunosuppressive therapies. We report 4 patients with drug-induced BP, three associated with dipeptidyl peptidase-4 inhibitors and one with immune checkpoint inhibitor, successfully treated with dupilumab. All four patients had failed or were intolerant to conventional therapies. Following dupilumab initiation, all patients experienced significant improvement in pruritus within 2 weeks. Complete remission was achieved in 3 patients within 1– 5 months of treatment and one patient had stable disease, enabling him to resume pembrolizumab therapy for esophageal cancer while on dupilumab. No significant adverse effects were reported during treatment periods. Our findings, supported by a literature review, suggest that dupilumab demonstrates promising efficacy and safety in treating drug-induced BP, with rapid improvement in pruritus and resolution of skin lesions. It may offer a valuable therapeutic alternative as a steroid sparing agent for elderly patients with multiple comorbidities and provides the potential to continue necessary medications (eg, cancer therapy) that may have triggered BP.
- 25 July 2026
- Published by Taylor & Francis in Expert Opinion on Pharmacotherapy
- Vol. 27 (12) , 1353-1366
Future directions for pharmaceutical management of alopecia areata in Asia
1. Alopecia areata (AA) is a chronic, immune-mediated, nonscarring hair disorder with a clinical spectrum ranging from limited patchy disease to alopecia totalis and alopecia universalis [1,2]. Alt...
- 25 July 2026
- Published by Taylor & Francis in Expert Opinion on Pharmacotherapy
- Vol. 27 (12) , 1353-1366
Future directions for pharmaceutical management of alopecia areata in Asia
1. Alopecia areata (AA) is a chronic, immune-mediated, nonscarring hair disorder with a clinical spectrum ranging from limited patchy disease to alopecia totalis and alopecia universalis [1,2]. Alt...
- Open Access
- 7 April 2026
- Published by Wiley in Journal of Cosmetic Dermatology
- Vol. 25 (4) , e70846
Efficacy of 1064‐nm Picosecond Laser in the Treatment of Lichen Planus Pigmentosus: A Split‐Face Randomized Controlled Trial
Background: Lichen planus pigmentosus (LPP) is an uncommon variant of lichen planus that causes visible pigmentation and significantly impacts quality of life. Current treatments for LPP are limited, with inconsistent outcomes from topical, oral, and laser therapies. The 1064‐nm picosecond laser has shown potential in managing pigmented skin disorders; however, evidence regarding its effect on LPP remains scarce. Objectives: This study aimed to evaluate the efficacy, safety, and patient satisfaction of the 1064‐nm picosecond laser in treating LPP. Methods: The study was a randomized, split‐face controlled trial. Twelve patients with biopsy‐confirmed LPP were enrolled, with one side of each participant treated with four sessions of the 1064‐nm picosecond laser at monthly intervals. The Modified Dermal Pigmentation Area and Severity Index (mDPASI) and melanin index (MI), assessed by three‐dimensional imaging, were measured before each treatment and at 1, 3, and 6 months following the last treatment. Physician global assessment (PGA) and patient satisfaction scores were assessed at 1 and 6 months following the last treatment. Additionally, adverse events were recorded. Results: A total of 12 patients with LPP, aged 55 ± 11.1 years, were recruited, and 11 completed the study. During the 6 months following the end of laser treatment, no significant differences were found in MI, mDPASI, or PGA between treatment and control groups. However, satisfaction scores showed a significant improvement on the treated side compared to the control. The mean overall pain score was 3.70 ± 1.72, with no major adverse events reported. Conclusion: The 1064‐nm picosecond laser demonstrated limited effectiveness in improving LPP clinical outcomes. Further studies with sham‐controlled trials and larger sample sizes are needed to optimize treatment parameters and sessions, and to validate the role of the picosecond laser as a therapeutic option for LPP.
- 7 April 2026
- Published by Wiley in Journal of Cosmetic Dermatology
- Vol. 25 (4) , e70846
Open AccessEfficacy of 1064‐nm Picosecond Laser in the Treatment of Lichen Planus Pigmentosus: A Split‐Face Randomized Controlled Trial
Background: Lichen planus pigmentosus (LPP) is an uncommon variant of lichen planus that causes visible pigmentation and significantly impacts quality of life. Current treatments for LPP are limited, with inconsistent outcomes from topical, oral, and laser therapies. The 1064‐nm picosecond laser has shown potential in managing pigmented skin disorders; however, evidence regarding its effect on LPP remains scarce. Objectives: This study aimed to evaluate the efficacy, safety, and patient satisfaction of the 1064‐nm picosecond laser in treating LPP. Methods: The study was a randomized, split‐face controlled trial. Twelve patients with biopsy‐confirmed LPP were enrolled, with one side of each participant treated with four sessions of the 1064‐nm picosecond laser at monthly intervals. The Modified Dermal Pigmentation Area and Severity Index (mDPASI) and melanin index (MI), assessed by three‐dimensional imaging, were measured before each treatment and at 1, 3, and 6 months following the last treatment. Physician global assessment (PGA) and patient satisfaction scores were assessed at 1 and 6 months following the last treatment. Additionally, adverse events were recorded. Results: A total of 12 patients with LPP, aged 55 ± 11.1 years, were recruited, and 11 completed the study. During the 6 months following the end of laser treatment, no significant differences were found in MI, mDPASI, or PGA between treatment and control groups. However, satisfaction scores showed a significant improvement on the treated side compared to the control. The mean overall pain score was 3.70 ± 1.72, with no major adverse events reported. Conclusion: The 1064‐nm picosecond laser demonstrated limited effectiveness in improving LPP clinical outcomes. Further studies with sham‐controlled trials and larger sample sizes are needed to optimize treatment parameters and sessions, and to validate the role of the picosecond laser as a therapeutic option for LPP.
- Open Access
- 4 March 2025
- Published by Wiley in Journal of Cosmetic Dermatology
- Vol. 24 (3) , e70029
Efficacy of Combined 595‐nm Pulsed Dye Laser and Intralesional Corticosteroids Versus Intralesional Corticosteroids Alone for Treating Postmastectomy Hypertrophic Scars and Keloids in Transgender Men: A Randomized Controlled Trial
Background: Top surgery masculinizes the chest appearance for transgender men (TM); however, some individuals may experience hypertrophic scars (HTS) or keloids following the surgery.Objectives: This study aimed to evaluate the efficacy of combined 595‐nm pulsed dye laser (PDL) and intralesional triamcinolone acetonide injection (IL TAC) compared to IL TAC monotherapy for treating HTS and keloids.Methods: Twenty‐five TM with 35 pairs of bilateral symmetric postmastectomy HTS or keloids were randomly allocated to receive the combined PDL and IL TAC on the scar(s) on one side of the chest and IL TAC monotherapy on the contralateral scar(s) in four monthly treatment sessions. Clinical improvement was evaluated using the Vancouver Scar Scale (VSS). Melanin index, hemoglobin index, and scar roughness were determined before each treatment session and at 1, 3, and 6 months after the last treatment. Participant‐rated satisfaction and adverse events were documented.Results: After two treatment sessions, scars treated with combined PDL and IL TAC demonstrated significantly greater improvements in the VSS (p = 0.012) and melanin index (p = 0.004) compared to those treated with IL TAC alone. The superior outcomes of the combined therapy persisted for 3 and 6 months after the end of treatment sessions for the VSS (p = 0.001) and melanin index (p = 0.048), respectively. Participants reported higher satisfaction for combined PDL and IL TAC than IL TAC monotherapy (p = 0.005). No serious or permanent adverse event was reported.Conclusion: The addition of 595‐nm PDL to IL TAC may provide more favorable outcomes for treating postmastectomy HTS and keloids among TM.
- 4 March 2025
- Published by Wiley in Journal of Cosmetic Dermatology
- Vol. 24 (3) , e70029
Open AccessEfficacy of Combined 595‐nm Pulsed Dye Laser and Intralesional Corticosteroids Versus Intralesional Corticosteroids Alone for Treating Postmastectomy Hypertrophic Scars and Keloids in Transgender Men: A Randomized Controlled Trial
Background: Top surgery masculinizes the chest appearance for transgender men (TM); however, some individuals may experience hypertrophic scars (HTS) or keloids following the surgery.Objectives: This study aimed to evaluate the efficacy of combined 595‐nm pulsed dye laser (PDL) and intralesional triamcinolone acetonide injection (IL TAC) compared to IL TAC monotherapy for treating HTS and keloids.Methods: Twenty‐five TM with 35 pairs of bilateral symmetric postmastectomy HTS or keloids were randomly allocated to receive the combined PDL and IL TAC on the scar(s) on one side of the chest and IL TAC monotherapy on the contralateral scar(s) in four monthly treatment sessions. Clinical improvement was evaluated using the Vancouver Scar Scale (VSS). Melanin index, hemoglobin index, and scar roughness were determined before each treatment session and at 1, 3, and 6 months after the last treatment. Participant‐rated satisfaction and adverse events were documented.Results: After two treatment sessions, scars treated with combined PDL and IL TAC demonstrated significantly greater improvements in the VSS (p = 0.012) and melanin index (p = 0.004) compared to those treated with IL TAC alone. The superior outcomes of the combined therapy persisted for 3 and 6 months after the end of treatment sessions for the VSS (p = 0.001) and melanin index (p = 0.048), respectively. Participants reported higher satisfaction for combined PDL and IL TAC than IL TAC monotherapy (p = 0.005). No serious or permanent adverse event was reported.Conclusion: The addition of 595‐nm PDL to IL TAC may provide more favorable outcomes for treating postmastectomy HTS and keloids among TM.
- Open Access
- 1 January 2025
- Published by Taylor & Francis in Clinical, Cosmetic and Investigational Dermatology
- Vol. ume 18, 31-36
Papular Acantholytic Dyskeratosis of the Vulva: A Case Report and Literature Review
Papular acantholytic dyskeratosis (PAD) of the vulva is an uncommon benign condition characterized by multiple hyperkeratotic papules in the anogenital region. First described in 1984, PAD belongs to the spectrum of focal acantholytic dyskeratoses and shares histopathological features with Darier disease and Hailey-Hailey disease. Despite its persistence, PAD is benign, requiring only reassurance in many cases. However, various treatment modalities have been reported for symptomatic patients, including topical and systemic therapies, and procedural interventions. We present a case of a 21-year-old Thai woman with asymptomatic perivulvar papules with typical histopathological features of PAD. After conservative management, the patient remained asymptomatic during follow-up. Additionally, we present a review of the current literature on this uncommon entity. This case highlights the importance of clinicopathological correlation in diagnosing PAD and distinguishing it from other clinically similar disorders. We discuss the clinical presentation, histopathological features, differential diagnosis, potential genetic associations, and management options for PAD.
- 1 January 2025
- Published by Taylor & Francis in Clinical, Cosmetic and Investigational Dermatology
- Vol. ume 18, 31-36
Open AccessPapular Acantholytic Dyskeratosis of the Vulva: A Case Report and Literature Review
Papular acantholytic dyskeratosis (PAD) of the vulva is an uncommon benign condition characterized by multiple hyperkeratotic papules in the anogenital region. First described in 1984, PAD belongs to the spectrum of focal acantholytic dyskeratoses and shares histopathological features with Darier disease and Hailey-Hailey disease. Despite its persistence, PAD is benign, requiring only reassurance in many cases. However, various treatment modalities have been reported for symptomatic patients, including topical and systemic therapies, and procedural interventions. We present a case of a 21-year-old Thai woman with asymptomatic perivulvar papules with typical histopathological features of PAD. After conservative management, the patient remained asymptomatic during follow-up. Additionally, we present a review of the current literature on this uncommon entity. This case highlights the importance of clinicopathological correlation in diagnosing PAD and distinguishing it from other clinically similar disorders. We discuss the clinical presentation, histopathological features, differential diagnosis, potential genetic associations, and management options for PAD.
- Open Access
- 1 August 2023
- Published by Taylor & Francis in Clinical, Cosmetic and Investigational Dermatology
- Vol. ume 16, 2259-2269
Trichoscopic Features of Syphilitic Alopecia and Alopecia Areata: A Comparative Study
Background: Syphilitic alopecia (SA) and alopecia areata (AA) are two distinct conditions that frequently present diagnostic difficulties, especially when differentiating between them due to their similar clinical presentations. Trichoscopy may help in differential diagnosis, but a comparison between trichoscopic features of SA and AA is yet to be researched. Objective: To compare trichoscopic features between SA and AA and determine their discriminative values. Methods: Electronic medical records and trichoscopic images of patients diagnosed with SA or AA between January 2000 and February 2022 were retrieved. Trichoscopic features were statistically compared, and their discriminative values were demonstrated as sensitivity, specificity, predictive value, likelihood ratio, and area under the receiver operating characteristic curve (AUC). Results: A total of 69 patients were included: 23 SA and 46 AA cases were matched with a 1:2 ratio. Black dots, broken hairs, pigtail hairs, exclamation mark hairs, tapered hairs, angulated hairs, and non-pigmented regrowing hairs were significantly more prevalent in AA than in SA (all P< 0.05), whereas erythematous background was more prevalent in SA than in AA patients (P=0.008). Among the aforementioned trichoscopic features, exclamation mark hairs and non-pigmented regrowing hairs had a high positive likelihood ratio for AA (16.17 and 8.34, respectively); however, only exclamation mark hairs revealed high AUC (AUC=0.816). Conclusion: Despite the presence of several similar trichoscopic features between SA and AA, trichoscopy can aid in distinguishing between the two diseases. Exclamation mark hairs are the only trichoscopic feature that can be used to differentiate patients with clinically suspicious SA from those with AA.
- 1 August 2023
- Published by Taylor & Francis in Clinical, Cosmetic and Investigational Dermatology
- Vol. ume 16, 2259-2269
Open AccessTrichoscopic Features of Syphilitic Alopecia and Alopecia Areata: A Comparative Study
Background: Syphilitic alopecia (SA) and alopecia areata (AA) are two distinct conditions that frequently present diagnostic difficulties, especially when differentiating between them due to their similar clinical presentations. Trichoscopy may help in differential diagnosis, but a comparison between trichoscopic features of SA and AA is yet to be researched. Objective: To compare trichoscopic features between SA and AA and determine their discriminative values. Methods: Electronic medical records and trichoscopic images of patients diagnosed with SA or AA between January 2000 and February 2022 were retrieved. Trichoscopic features were statistically compared, and their discriminative values were demonstrated as sensitivity, specificity, predictive value, likelihood ratio, and area under the receiver operating characteristic curve (AUC). Results: A total of 69 patients were included: 23 SA and 46 AA cases were matched with a 1:2 ratio. Black dots, broken hairs, pigtail hairs, exclamation mark hairs, tapered hairs, angulated hairs, and non-pigmented regrowing hairs were significantly more prevalent in AA than in SA (all P< 0.05), whereas erythematous background was more prevalent in SA than in AA patients (P=0.008). Among the aforementioned trichoscopic features, exclamation mark hairs and non-pigmented regrowing hairs had a high positive likelihood ratio for AA (16.17 and 8.34, respectively); however, only exclamation mark hairs revealed high AUC (AUC=0.816). Conclusion: Despite the presence of several similar trichoscopic features between SA and AA, trichoscopy can aid in distinguishing between the two diseases. Exclamation mark hairs are the only trichoscopic feature that can be used to differentiate patients with clinically suspicious SA from those with AA.
- Open Access
- 1 August 2023
- Published by Taylor & Francis in Clinical, Cosmetic and Investigational Dermatology
- Vol. ume 16, 2073-2082
Differences in Demographic and Clinical Characteristics Among Subtypes of Female Pattern Hair Loss
Background: Female pattern hair loss (FPHL) is the most common hair loss disorder in women that can be classified into three patterns, including Ludwig, Olsen, and Hamilton-Norwood subtypes. Information regarding the comparison of demographics, clinical characteristics, and associated comorbidities among subtypes of FPHL is scarce and contradictory. Objective: To evaluate and compare the epidemiology, clinical manifestations, and comorbid conditions of FPHL subtypes and determine their associated factors. Methods: This retrospective study included patients who were diagnosed with FPHL between January 2000 and November 2021. Participants were classified into three subtypes, namely Ludwig, Olsen, and Hamilton-Norwood, and were statistically compared. Variables significantly associated with each FPHL subtype were identified using multivariable multinomial logistic regression analysis. Results: Among the 519 patients with FPHL, the Ludwig subtype was the most prevalent (51.1%), followed by the Olsen (32.9%) and Hamilton-Norwood (16%) subtypes. The Hamilton-Norwood subtype revealed significantly higher frequencies of early disease onset (61.4%), menstrual irregularity (22.9%), polycystic ovary syndrome (PCOS, 18.1%), and seborrhea (30.1%) but lower frequencies of overweight (24.1%) and type 2 diabetes mellitus (DM, 2.4%). Multivariable multinomial regression analysis demonstrated that the Hamilton-Norwood subtype was a predictor for early disease onset and PCOS compared to Ludwig (early onset: odds ratio (OR) = 2.14, 95% confidence interval (CI) = 1.39– 4.22, P = 0.02; PCOS: OR = 2.02, 95% CI = 1.55– 4.84, P = 0.03), and Olsen (early onset: OR = 1.89, 95% CI = 1.03– 3.92, P = 0.04; PCOS: OR = 2.24, 95% CI = 1.89– 5.31, P = 0.01). In contrast, the Hamilton-Norwood pattern was at decreased risk for type 2 DM compared to Ludwig (OR = 0.51, 95% CI = 0.03– 0.82, P = 0.02), and Olsen (OR = 0.68, 95% CI = 0.04– 0.79, P = 0.03). Conclusion: The Ludwig pattern was found to be the most prevalent FPHL subtype among Thai patients. Moreover, the Hamilton-Norwood subtype was associated with early disease onset and PCOS, whereas the Ludwig and Olsen subtypes were associated with type 2 DM.
- 1 August 2023
- Published by Taylor & Francis in Clinical, Cosmetic and Investigational Dermatology
- Vol. ume 16, 2073-2082
Open AccessDifferences in Demographic and Clinical Characteristics Among Subtypes of Female Pattern Hair Loss
Background: Female pattern hair loss (FPHL) is the most common hair loss disorder in women that can be classified into three patterns, including Ludwig, Olsen, and Hamilton-Norwood subtypes. Information regarding the comparison of demographics, clinical characteristics, and associated comorbidities among subtypes of FPHL is scarce and contradictory. Objective: To evaluate and compare the epidemiology, clinical manifestations, and comorbid conditions of FPHL subtypes and determine their associated factors. Methods: This retrospective study included patients who were diagnosed with FPHL between January 2000 and November 2021. Participants were classified into three subtypes, namely Ludwig, Olsen, and Hamilton-Norwood, and were statistically compared. Variables significantly associated with each FPHL subtype were identified using multivariable multinomial logistic regression analysis. Results: Among the 519 patients with FPHL, the Ludwig subtype was the most prevalent (51.1%), followed by the Olsen (32.9%) and Hamilton-Norwood (16%) subtypes. The Hamilton-Norwood subtype revealed significantly higher frequencies of early disease onset (61.4%), menstrual irregularity (22.9%), polycystic ovary syndrome (PCOS, 18.1%), and seborrhea (30.1%) but lower frequencies of overweight (24.1%) and type 2 diabetes mellitus (DM, 2.4%). Multivariable multinomial regression analysis demonstrated that the Hamilton-Norwood subtype was a predictor for early disease onset and PCOS compared to Ludwig (early onset: odds ratio (OR) = 2.14, 95% confidence interval (CI) = 1.39– 4.22, P = 0.02; PCOS: OR = 2.02, 95% CI = 1.55– 4.84, P = 0.03), and Olsen (early onset: OR = 1.89, 95% CI = 1.03– 3.92, P = 0.04; PCOS: OR = 2.24, 95% CI = 1.89– 5.31, P = 0.01). In contrast, the Hamilton-Norwood pattern was at decreased risk for type 2 DM compared to Ludwig (OR = 0.51, 95% CI = 0.03– 0.82, P = 0.02), and Olsen (OR = 0.68, 95% CI = 0.04– 0.79, P = 0.03). Conclusion: The Ludwig pattern was found to be the most prevalent FPHL subtype among Thai patients. Moreover, the Hamilton-Norwood subtype was associated with early disease onset and PCOS, whereas the Ludwig and Olsen subtypes were associated with type 2 DM.
- Open Access
- 1 June 2023
- Published by Taylor & Francis in Clinical, Cosmetic and Investigational Dermatology
- Vol. ume 16, 1589-1593
Pretibial Pruritic Papular Dermatitis: A Case Report and Emphasis on Effective Treatment with Pentoxifylline
Pretibial pruritic papular dermatitis (PPPD) is a distinctive skin disorder in response to persistent pretibial manipulation. Clinically, it manifests as multiple discrete, pruritic, flesh-colored-to-erythematous papules and plaques confined to the pretibial area. The histological hallmark of PPPD comprises irregular epidermal psoriasiform hyperplasia with parakeratosis and spongiosis, dermal fibrosis, and lymphohistiocytic infiltration. Due to its rarity and underrecognition, the prevalence and standard treatment of the disease have yet to be well elucidated. Here, we present a case of PPPD in a 60-year-old female presenting with numerous pruritic, erythematous-to-brownish papules and plaques on bilateral pretibial areas for 1.5 years. The lesions were significantly improved after 1 month of additional treatment with oral pentoxifylline. In this report, we aim to raise awareness in recognizing PPPD since it manifests unique clinical, dermoscopic, and histological features, representing pretibial skin’s response to chronic rubbing. In addition, we proposed a novel effective therapy for the disease using pentoxifylline.
- 1 June 2023
- Published by Taylor & Francis in Clinical, Cosmetic and Investigational Dermatology
- Vol. ume 16, 1589-1593
Open AccessPretibial Pruritic Papular Dermatitis: A Case Report and Emphasis on Effective Treatment with Pentoxifylline
Pretibial pruritic papular dermatitis (PPPD) is a distinctive skin disorder in response to persistent pretibial manipulation. Clinically, it manifests as multiple discrete, pruritic, flesh-colored-to-erythematous papules and plaques confined to the pretibial area. The histological hallmark of PPPD comprises irregular epidermal psoriasiform hyperplasia with parakeratosis and spongiosis, dermal fibrosis, and lymphohistiocytic infiltration. Due to its rarity and underrecognition, the prevalence and standard treatment of the disease have yet to be well elucidated. Here, we present a case of PPPD in a 60-year-old female presenting with numerous pruritic, erythematous-to-brownish papules and plaques on bilateral pretibial areas for 1.5 years. The lesions were significantly improved after 1 month of additional treatment with oral pentoxifylline. In this report, we aim to raise awareness in recognizing PPPD since it manifests unique clinical, dermoscopic, and histological features, representing pretibial skin’s response to chronic rubbing. In addition, we proposed a novel effective therapy for the disease using pentoxifylline.